###begin article-title 0
###xml 14 20 14 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTPN22</italic>
###xml 80 88 <span type="species:ncbi:9606">patients</span>
Evaluation of PTPN22 polymorphisms and Vogt-Koyanagi-Harada disease in Japanese patients
###end article-title 0
###begin p 1
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Purpose
###end title 2
###begin p 3
###xml 154 160 154 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTPN22</italic>
###xml 388 394 388 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTPN22</italic>
Vogt-Koyanagi-Harada (VKH) disease is an autoimmune disorder against melanocytes. Polymorphisms of the protein tyrosine phosphatase non-receptor 22 gene (PTPN22) have recently been reported to be associated with susceptibility to several autoimmune diseases. In this study, genetic susceptibility to VKH disease was investigated by screening for single nucleotide polymorphisms (SNPs) of PTPN22.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 161 167 161 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTPN22</italic>
###xml 24 32 <span type="species:ncbi:9606">patients</span>
A total of 167 Japanese patients with VKH disease and 188 healthy Japanese controls were genotyped by direct sequencing methods for six SNPs (, , , , , and ) of PTPN22 including the uncoding exons.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 16 22 16 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTPN22</italic>
The six SNPs in PTPN22 showed no significant association with susceptibility to VKH disease or its ocular, neurologic, or dermatological manifestation.
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
Further studies are needed to clarify the genetic mechanisms underlying VKH disease.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 90 91 90 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 182 183 182 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 184 185 184 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 264 265 264 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 266 267 266 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 490 493 490 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA</italic>
###xml 494 499 494 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-DRB1</italic>
###xml 509 510 509 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 511 512 511 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 465 470 <span type="species:ncbi:9606">human</span>
Vogt-Koyanagi-Harada (VKH) disease is one of the most frequent forms of uveitis in Japan [1]. It is characterized as bilateral panuveitis accompanied by neurologic and skin lesions [2,3]. This disease is considered to be an autoimmune disease against melanocytes [4,5]. Though the etiology of VKH disease still remains unknown, genetic factors may play an important role in susceptibility as indicated by an established association between VKH disease and specific human leukocyte antigen (HLA)-DRB1 alleles [6,7].
###end p 11
###begin p 12
###xml 55 61 55 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTPN22</italic>
###xml 237 238 237 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 239 241 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 325 331 325 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTPN22</italic>
###xml 509 511 509 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 512 514 512 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 524 530 524 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTPN22</italic>
###xml 735 736 735 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
The protein tyrosine phosphatase non-receptor 22 gene (PTPN22) is located on chromosome 1p13.3-p13.1, and it encodes the lymphoid-specific phosphatase (Lyp) that is important in the negative control of T-cell activation and development [8-10]. Recently, it was reported the single nucleotide polymorphism (SNP), R620W (), in PTPN22 increased susceptibility to several autoimmune diseases including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and insulin dependent diabetes mellitus (IDDM) [11-15]. In the PTPN22 risk variant (), this substitution disrupts an interaction between Lyp and the protein tyrosine kinase, Csk, and may translate biologically to a potential for 'hyperreactive' pathogenic T-cell responses [8].
###end p 12
###begin p 13
###xml 65 67 65 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
###xml 68 70 68 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 177 183 177 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTPN22</italic>
###xml 321 323 321 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 324 326 324 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
This R620W mutation was not observed in the Japanese population [16,17]. Therefore, in this study, we analyzed six SNPs, which belong to the same haplotype block as R620W () in PTPN22. For the efficacy of the linkage analysis, we chose six SNPs of which minor allele frequencies were more than 15% from the database of  [18,19].
###end p 13
###begin title 14
Methods
###end title 14
###begin p 15
###xml 234 235 234 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 47 55 <span type="species:ncbi:9606">patients</span>
###xml 101 109 <span type="species:ncbi:9606">patients</span>
###xml 146 154 <span type="species:ncbi:9606">Patients</span>
###xml 380 388 <span type="species:ncbi:9606">patients</span>
We recruited 167 VKH (72 males and 95 females) patients and 188 healthy controls for this study. All patients and control subjects were Japanese. Patients were diagnosed according to the "Revised Diagnostic Criteria for VKH Disease" [3] at the Uveitis Survey Clinic of the Hokkaido University Hospital (Sapporo, Japan) and Yokohama City University Hospital (Yokohama, Japan). All patients and control subjects were informed of the study's purpose, and their consent obtained. The study was approved by the ethics committee from each institute participating in this study.
###end p 15
###begin p 16
###xml 144 150 144 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTPN22</italic>
###xml 173 181 173 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1</xref>
###xml 265 272 265 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 484 491 484 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
DNA was prepared from peripheral blood specimens using the QIAamp DNA Blood Mini Kit (Qiagen, Tokyo, Japan). Six SNPs (, , , , , and ) from the PTPN22 region were examined (Figure 1). Each of the six SNPs was amplified by standard polymerase chain reactions (PCRs; Table 1). After purification using ExoSAP-IT (USB Corporation, Cleveland, OH), the PCR products were sequenced with Big Dye Terminator v3.1 (Applied Biosystems, Foster City, CA) using either sense or antisense primers (Table 1). The BigDye XTerminator Purification Kit (Applied Biosystems) was used to purify the DNA from sequencing reactions. The sequencing reactions were analyzed using an ABI3130 sequencer (Applied Biosystems).
###end p 16
###begin p 17
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTPN22</italic>
PTPN22 structure with two transcript isoforms and six SNP. Six SNP variants with minor allele frequencies 15% from the database of . The black and white areas in the exons indicate the UTR and coding region, respectively.
###end p 17
###begin title 18
###xml 16 22 16 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTPN22</italic>
PCR primers for PTPN22 SNPs.
###end title 18
###begin p 19
The position of the SNPs is cited from the NCBI database.
###end p 19
###begin title 20
Statistical analysis
###end title 20
###begin p 21
###xml 203 204 201 202 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 306 312 304 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTPN22</italic>
###xml 559 561 557 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
For statistical analyses, the Hardy-Weinberg equilibrium was tested for each SNP among the control subjects. Genotype frequency differences between the case and control genotypes were assessed by the chi2 test. The calculation of linkage disequilibrium (LD) and pair-wise LD (D' value) between SNPs of the PTPN22 region and the haplotypes was performed with  software, version 3.32. The maximum likelihood estimates of haplotype frequencies were estimated by pairs of unphased genotypes using the expectation-maximization (EM) algorithms in the R package '' [20].
###end p 21
###begin title 22
Results
###end title 22
###begin p 23
###xml 278 285 278 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2">Table 2</xref>
###xml 658 664 658 664 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTPN22</italic>
###xml 666 674 666 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2</xref>
###xml 828 834 828 834 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTPN22</italic>
###xml 922 928 922 928 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTPN22</italic>
###xml 101 109 <span type="species:ncbi:9606">patients</span>
###xml 304 312 <span type="species:ncbi:9606">patients</span>
Allele frequencies for the six SNPs covering the gene were in Hardy-Weinberg equilibrium in both the patients and controls. The allelic frequency of each SNP in both groups was nearly equal, and no association was detected when compared independently (odds ratio, OR 1.14-1.35; Table 2). Stratifying the patients by the presence of diffuse choroiditis, sunset glow fundus, nummular chorioretinal depigmented spots, neurologic auditory involvement, meningismus, tinnitus, cerebrospinal fluid pleocytosis, or integumentary findings also revealed no evidence of association in VKH disease (data not shown). We calculated pairwise D' values for all SNP pairs in PTPN22 (Figure 2). The pairwise D' values in the gene were nearly 1 among almost all SNP pairs, indicating the SNPs were highly associated with each other and the entire PTPN22 was contained within a single LD block. Haplotype analysis predicted and revealed that PTPN22 was not associated with VKH disease in this Japanese cohort (data not shown).
###end p 23
###begin title 24
###xml 28 36 <span type="species:ncbi:9606">patients</span>
Genotype frequencies in VKH patients and controls.
###end title 24
###begin p 25
###xml 66 74 <span type="species:ncbi:9606">patients</span>
###xml 130 138 <span type="species:ncbi:9606">patients</span>
The above table is the genotype and allele frequencies of the VKH patients and healthy controls. There are no differences between patients and controls.
###end p 25
###begin p 26
###xml 45 51 45 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTPN22</italic>
###xml 120 127 <span type="species:ncbi:9606">patient</span>
D' score for the six SNPs studied across the PTPN22 haplotype. Black cells indicate that D' is greater than 0.9. Upper: patient population, lower: control population. The figure indicates that the six SNPs were in all the same haplotype block.
###end p 26
###begin title 27
Discussion
###end title 27
###begin p 28
###xml 75 81 75 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTPN22</italic>
###xml 193 194 193 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 207 213 207 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTPN22</italic>
###xml 314 316 314 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 317 319 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 320 322 320 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 323 325 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 488 489 488 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 490 492 490 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 493 495 493 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 591 597 591 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTPN22</italic>
###xml 599 607 599 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 742 744 742 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 95 103 <span type="species:ncbi:9606">patients</span>
In the present study, we analyzed polymorphisms of the new candidate gene, PTPN22, in Japanese patients with VKH disease. The gene encodes an important negative regulator of T cell activation [9]. An SNP of PTPN22, R620W () was reported to be associated with several autoimmune diseases such as RA, SLE, and IDDM [11,12,14,15]. However, this SNP, which disrupts an interaction between Lyp and the protein tyrosine kinase, Csk, does not exist as a polymorphism in the Japanese population [9,10,12]. Therefore, in this study, we examined six other SNPs to evaluate the susceptibility locus of PTPN22. HLA-DRB1 is a common genetic factor in autoimmune diseases (RA and IDDM). Therefore, there may be other common genetic factors in VKH disease [21].
###end p 28
###begin p 29
###xml 75 76 75 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 77 78 77 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 237 239 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 446 447 446 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 448 449 448 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 577 588 577 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*04</italic>
###xml 629 640 629 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*04</italic>
###xml 662 673 662 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*04</italic>
###xml 699 700 699 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 701 703 701 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r23">23</xref>
###xml 761 772 761 772 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*04</italic>
###xml 774 775 774 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 862 863 862 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 864 865 864 865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 866 868 866 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r24">24</xref>
###xml 869 871 869 871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r25">25</xref>
###xml 922 933 922 933 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*04</italic>
###xml 944 945 944 945 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 969 980 969 980 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*04</italic>
###xml 1149 1152 1149 1152 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TYR</italic>
###xml 1190 1195 1190 1195 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TYRP1</italic>
###xml 1233 1238 1233 1238 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TYRP2</italic>
###xml 1257 1266 1257 1262 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IFN-&#947;</italic>
###xml 1341 1342 1337 1338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 1343 1345 1339 1341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r26">26</xref>
###xml 1473 1475 1469 1471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r27">27</xref>
###xml 1476 1478 1472 1474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r29">29</xref>
###xml 192 200 <span type="species:ncbi:9606">patients</span>
###xml 436 444 <span type="species:ncbi:9606">patients</span>
###xml 480 485 <span type="species:ncbi:9606">human</span>
###xml 602 610 <span type="species:ncbi:9606">patients</span>
###xml 650 658 <span type="species:ncbi:9606">patients</span>
###xml 691 697 <span type="species:ncbi:9606">people</span>
###xml 749 755 <span type="species:ncbi:9606">people</span>
###xml 787 793 <span type="species:ncbi:9606">people</span>
###xml 892 900 <span type="species:ncbi:9606">patients</span>
VKH disease is considered to be an autoimmune disease against melanocytes [2-5]. In early studies, activated T lymphocytes were elevated and attacked melanocytes of ocular choroidal tissue in patients in the active phase of VKH disease [22]. Antigen-specific T-cell assay revealed that peptide fragments of the tyrosinase family proteins (tyrosinase, tyrosinase related protein 1 and 2) proliferated in T lymphocytes collected from VKH patients [4,5]. These proteins are found in human melanocytes. These antigen-specific T cell responses were detected in cells collected from HLA-DRB1*04 positive VKH patients only but not from HLA-DRB1*04 negative patients or HLA-DRB1*04 positive healthy people [7,23]. In the Japanese population, 40% of healthy people have HLA-DRB1*04 [7]. However, people having VKH disease represent only 0.01% of the Japanese population [1,7,24,25]. In addition, some patients with VKH disease are HLA-DRB1*04 negative [7]. Thus, it is believed HLA-DRB1*04 is a major susceptible gene in VKH disease. However, other minor genetic factors still remain unclear. To find other susceptible genes, we studied the tyrosinase gene (TYR), tyrosinase related protein 1 gene (TYRP1), tyrosinase related protein 2 gene (TYRP2), and interferon (IFN-gamma), but we could not find any association with these genes and VKH disease [7,26]. Genetic influences of VKH were also investigated in other countries, but the etiology of the disease seems to be unresolved [27-29].
###end p 29
###begin p 30
###xml 47 53 47 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTPN22</italic>
In this study, we found no association between PTPN22 and VKH disease in the individuals studied. Our results suggest that further molecular genetic studies are needed to detect novel genetic loci and predisposing genes and to elucidate the true genetic mechanisms underlying VKH disease.
###end p 30
###begin title 31
Acknowledgments
###end title 31
###begin p 32
This work was supported by Grant-in-Aid for Scientific Research (Category B, No. 19406028) from the Ministry of Education, Culture, Science, Sports and Technology (MEXT), Japan.
###end p 32
###begin title 33
References
###end title 33
###begin article-title 34
Epidemiological survey of intraocular inflammation in Japan.
###end article-title 34
###begin article-title 35
Comparative study of two sets of criteria for the diagnosis of Vogt-Koyanagi-Harada's disease.
###end article-title 35
###begin article-title 36
Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature.
###end article-title 36
###begin article-title 37
Tyrosinase family proteins are antigens specific to Vogt-Koyanagi-Harada disease.
###end article-title 37
###begin article-title 38
###xml 65 69 <span type="species:ncbi:9615">dogs</span>
Experimentally induced Vogt-Koyanagi-Harada disease in two Akita dogs.
###end article-title 38
###begin article-title 39
HLA class II genes in Vogt-Koyanagi-Harada disease.
###end article-title 39
###begin article-title 40
###xml 68 76 <span type="species:ncbi:9606">patients</span>
Tyrosinase gene family and Vogt-Koyanagi-Harada disease in Japanese patients.
###end article-title 40
###begin article-title 41
A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes.
###end article-title 41
###begin article-title 42
PTPN22 and autoimmune disease.
###end article-title 42
###begin article-title 43
Gaining insight into PTPN22 and autoimmunity.
###end article-title 43
###begin article-title 44
A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis.
###end article-title 44
###begin article-title 45
###xml 90 95 <span type="species:ncbi:9606">human</span>
Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE.
###end article-title 45
###begin article-title 46
###xml 75 80 <span type="species:ncbi:9606">human</span>
Linkage proof for PTPN22, a rheumatoid arthritis susceptibility gene and a human autoimmunity gene.
###end article-title 46
###begin article-title 47
Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes.
###end article-title 47
###begin article-title 48
###xml 189 197 <span type="species:ncbi:9606">patients</span>
Association analysis of the R620W polymorphism of protein tyrosine phosphatase PTPN22 in systemic lupus erythematosus families: increased T allele frequency in systemic lupus erythematosus patients with autoimmune thyroid disease.
###end article-title 48
###begin article-title 49
Associations of protein tyrosine phosphatase nonreceptor 22 (PTPN22) gene polymorphisms with susceptibility to Graves' disease in a Japanese population.
###end article-title 49
###begin article-title 50
Haplotype analysis revealed no association between the PTPN22 gene and RA in a Japanese population.
###end article-title 50
###begin article-title 51
JSNP: a database of common gene variations in the Japanese population.
###end article-title 51
###begin article-title 52
###xml 128 133 <span type="species:ncbi:9606">human</span>
Gene-based SNP discovery as part of the Japanese Millennium Genome Project: identification of 190,562 genetic variations in the human genome. Single-nucleotide polymorphism.
###end article-title 52
###begin article-title 53
Score tests for association between traits and haplotypes when linkage phase is ambiguous.
###end article-title 53
###begin article-title 54
Association of the B-cell alloantigen DRw4 with rheumatoid arthritis.
###end article-title 54
###begin article-title 55
Vogt-Koyanagi-Harada syndrome.
###end article-title 55
###begin article-title 56
HLA-DRB1 typing of Vogt-Koyanagi-Harada's disease by PCR-RFLP and the strong association with DRB1*0405 and DRB1*0410.
###end article-title 56
###begin article-title 57
Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis.
###end article-title 57
###begin article-title 58
Allele frequencies and haplotypic associations defined by allelic DNA typing at HLA class I and class II loci in the Japanese population.
###end article-title 58
###begin article-title 59
Polymorphism of IFN-gamma gene and Vogt-Koyanagi-Harada disease.
###end article-title 59
###begin article-title 60
Association of the CTLA-4 gene with Vogt-Koyanagi-Harada syndrome.
###end article-title 60
###begin article-title 61
Small ubiquitin-like modifier 4 (SUMO4) polymorphisms and Vogt-Koyanagi-Harada (VKH) syndrome in the Chinese Han population.
###end article-title 61
###begin article-title 62
###xml 74 82 <span type="species:ncbi:9606">patients</span>
PDCD1 genes may protect against extraocular manifestations in Chinese Han patients with Vogt-Koyanagi-Harada syndrome.
###end article-title 62

